Agnese Fragassi

Agnese Fragassi


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2024 in Journal of Xenobiotics
Verified
Journal Article
Open access
PDF file
AFAgnese Fragassi
Agnese Fragassi
AGAntonietta Greco
Antonietta Greco
RPRoberto Palomba
Roberto Palomba
Osteoarthritis (OA) is a debilitating joint disease characterized by cartilage degradation, leading to pain and functional impairment. A key contributor to OA progression is the decline in cartilage lubrication. In physiological conditions, synovial fluid (SF) macromolecules like hyaluronic acid (HA), phospholipids, and lubricin play a crucial role in the boundary lubrication of articular cartilage. In early OA, cartilage damage triggers inflammation, altering SF composition and compromising the lubrication layer. This increases friction between mating interfaces, worsening cartilage degradation and local inflammation. Therefore, early-stage restoration of lubrication (by injecting in the joint different classes of compounds and formulations) could alleviate, and potentially reverse, OA progression. In the light of this, a broad variety of lubricants have been investigated for their ability to reduce friction in OA joints and promote cartilage repair in clinical and preclinical studies. This review examines recent advancements in lubricant-based therapy for OA, focusing on natural, bioinspired, and alternative products. Starting from the currently applied therapy, mainly based on natural lubricants as HA, we will present their modified versions, either in hydrogel form or with specific biomimetic moieties with the aim of reducing their clearance from the joint and of enhancing their lubricating properties. Finally, the most advanced and recent formulation, represented by alternative strategies, will be proposed. Particular emphasis will be placed on those ones involving new types of hydrogels, microparticles, nanoparticles, and liposomes, which are currently under investigation in preclinical studies. The potential application of particles and liposomes could foster the transition from natural lubricants to Drug Delivery Systems (DDSs) with lubricant features; transition which could provide more complete OA treatments, by simultaneously providing lubrication replacement and sustained release of different payloads and active agents directly at the joint level. Within each category, we will examine relevant preclinical studies, highlighting challenges and future prospects.

14 November 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
FFFederica Foglietta
Federica Foglietta
AFAgnese Fragassi
Agnese Fragassi
CPCristiano Pesce
Cristiano Pesce
FAFrancisco Andres Soto Arratia
Francisco Andres Soto Arratia
AMAlberto Mangia
Alberto Mangia
SSStefano Salmaso
Stefano Salmaso
Both doxorubicin and gold nanoparticles (GNPs) exhibit sonosensitising properties, significantly increasing the production of cytotoxic reactive oxygen species (ROS) when exposed to ultrasound (US). Ultrasound-responsive, targeted GNPs decorated with a pH-releasable doxorubicin prodrug (FDGNPs) have been developed to exploit this synergistic effect, enabling highly selective and effective anticancer activity. The GNPs were produced using the Turkevich method and functionalised with folate-PEG3.5 kDa-SH as the targeting agent (FGNPs). These were then decorated with doxorubicin derivatised with lipoic acid via a pH-sensitive linker and stabilised with a mPEG2 kDa-SH coating. The FDGNPs' cell targeting, uptake and anticancer effects were evaluated in an epidermoid carcinoma cell line expressing a high level of folate receptor (KB-hFR), which was cultured as monolayers and three-dimensional spheroids. The anticancer effects of the US-exposed FDGNPs were evaluated in terms of cell viability, ROS production and cell death. FDGNPs selectively associated to KB cells in a folate-dependent manner. Ultrasound-exposed FDGNPs resulted in a significant decrease in KB-hFR cell viability of up to 70 %, increased ROS of up to 50 %, and increased necrotic cells of up to 45 %, compared to untreated cells. Furthermore, switching from a custom-built US device to a standardised US scanning device confirmed that US exposure effectively elicits the anticancer activity of FDGNPs in KB-hFR spheroids, resulting in a 45 % decrease in cell viability. GNPs have been engineered to provide active targeting and controlled drug release while exploiting their sonosensitising properties; therefore, this platform shows promise in improving the selectivity and efficacy of cancer therapy.